The Future of CAR T, Novel Therapies and Treatment Gaps in R/R LBCL

There is an evolving landscape in the use of CAR T-cell therapy and bispecific antibodies for treating LBCL. Current clinical trials are investigating new CAR T targets beyond the traditional CD19 and CD20, including innovative approaches that target multiple antigens simultaneously. These advancements may lead to new treatment approvals in the near future. Additionally, there is growing interest in sequencing CAR T therapy and bispecific agents to improve minimal residual disease control after initial treatment. Whether these therapies will be used in combination or as frontline treatments remains to be seen and is the subject of ongoing research.

Both CAR T-cell therapies and bispecific antibodies have become key components in managing LBCL. These therapies offer more targeted options that could potentially reduce the need for traditional cytotoxic chemotherapy. The goal is to improve overall patient outcomes by achieving durable responses while minimizing long-term toxicities, such as infections and secondary malignancies. The increasing availability of these targeted treatments is expected to shift treatment paradigms toward more personalized and less toxic approaches.

Optimizing patient access to CAR T-cell therapy remains a critical challenge. Despite many eligible patients, a relatively small percentage actually receive referrals to specialized treatment centers. Improving early referral processes and developing financial assistance programs are essential to increase access. Equally important is enhancing patient monitoring and management after therapy, including safe protocols for outpatient follow-up and support for local health care providers. By addressing these challenges through coordinated efforts, more patients can benefit from potentially curative therapies while maintaining close monitoring and management throughout their treatment journey.